Starling Oncology (STLNW) EBITDA (2020 - 2026)

Starling Oncology (STLNW) has reported EBITDA for 7 consecutive years, with -$3.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 65.67% year-over-year to -$3.5 million; the trailing twelve-month figure through Jun 2026 stood at -$22.1 million (up 48.65% YoY), and the FY2025 full-year result was -$32.1 million, up 43.58% from the prior year.
• EBITDA improved to -$3.5 million in Q2 2026 per STLNW's latest filing, from -$5.6 million in the prior quarter.
• Across five years, EBITDA topped out at -$3.5 million in Q2 2026 and bottomed at -$32.3 million in Q1 2023.
• Historically, EBITDA has averaged -$14.0 million across 5 years, with a median of -$13.7 million in 2023.
• The sharpest annual moves came in 2022 and 2026: EBITDA tumbled 1802.97% in 2022, then soared 65.67% in 2026.
• Over 5 years, EBITDA stood at -$24.6 million in 2022, then surged by 41.18% to -$14.5 million in 2023, then climbed by 24.06% to -$11.0 million in 2024, then surged by 45.51% to -$6.0 million in 2025, then surged by 41.69% to -$3.5 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$3.5 million, -$5.6 million, and -$6.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.